赛特医药 (referred to in the article as 赛特明强) develops innovative small-molecule therapeutics using an AI-driven, ultra-large-scale drug design and screening platform called SigmaHit®. The company focuses its R&D on oncology, autoimmune diseases, and central nervous system indications. It leverages advanced research technologies and substantial computing resources to identify optimal solutions for patients in China and globally. In April 2024 the company completed an A+ financing round raising over ¥100 million. Investors named in the round include Taige Equity Investment, Lichen Investment and Zhizhong Investment among other professional institutions. The proceeds are earmarked to accelerate clinical trial work for its anti-tumor candidates ST-1898 and ST-1703.

Total raised

$14M

Funding rounds

1

Latest round

Series A

Latest activity

Apr 2024